Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Fonction du locus coeruleus chez les personnes âgées normales et le risque de MA (LEAD)

4 novembre 2026 mis à jour par: NYU Langone Health

Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.

Aperçu de l'étude

Description détaillée

The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).

Type d'étude

Interventionnel

Inscription (Réel)

34

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • New York
      • New York, New York, États-Unis, 10029
        • Icahn School of Medicine Mount Sinai
      • New York, New York, États-Unis, 10016
        • NYU Grossman School of Medicine

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

55 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male and female subjects with normal cognition and 55-75 years of age will be enrolled.
  • Subjects will be within normal limits on neurological and psychiatric examinations.
  • All subjects enrolled will have a CDR of 0. This will be evaluated through a clinical interview administered by a study physician (informant interview will not be required).
  • All subjects will have had a minimum of 12 years of education.

Exclusion Criteria:

  • History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, stroke, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
  • Significant history of alcoholism or drug abuse.
  • Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or life-long history of major depression).
  • Geriatric Depression Scale (short form)>6.
  • Insulin dependent diabetes.
  • Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological conditions.
  • Physical impairment of such severity as to adversely affect the validity of psychological testing.
  • Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
  • History of a first-degree family member with early onset (age <60 years) dementia.
  • Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA (AHI4%≥15).
  • Taking Coumadin/warfarin and/or medications affecting cognition or sleep.
  • Failure to complete all study visit within 4 months

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Personnes âgées cognitivement normales (NC)

Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.

Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.

PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]O-methylreboxetine ([11C]MRB) to measure NET availability.

Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Délai: Visit 4 (1-4 weeks after LP that occurred on day 14)
Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
Délai: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.

Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Levels of Hyperphosphorylated Tau (P-Tau)
Délai: Visit 4 (1-4 weeks after LP that occurred on day 14)

Levels will be derived from the plasma and reported in pg/mL

Visit 4 (1-4 weeks after LP that occurred on day 14)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Ricardo Osorio, NYU Langone Health

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 août 2020

Achèvement primaire (Réel)

26 mars 2024

Achèvement de l'étude (Réel)

26 mars 2024

Dates d'inscription aux études

Première soumission

21 mai 2020

Première soumission répondant aux critères de contrôle qualité

21 mai 2020

Première publication (Réel)

27 mai 2020

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

All of the individual participant data collected during the trial, after deidentification.

Délai de partage IPD

Immediately following publication. No end date.

Critères d'accès au partage IPD

The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner